Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial.

Cancer Res Treat · 2019 · PMC6639223 · PMID 30282447

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not achieve significanceno p-value reported

Safety The incidences of grade 3/4 leukopenia and neutropenia were slightly increased with R-CHOP-21 compared to R-CHOP-14, but this difference did not achieve significance.

also in 1,397 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.